Esther Ellen Freeman, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Sarcoma, Kaposi | 16 | 2024 | 375 | 7.020 |
Why?
|
Dermatology | 21 | 2024 | 907 | 6.250 |
Why?
|
Skin Diseases | 14 | 2023 | 1088 | 5.070 |
Why?
|
Chilblains | 5 | 2022 | 17 | 3.120 |
Why?
|
HIV Infections | 27 | 2024 | 17533 | 1.560 |
Why?
|
Registries | 16 | 2022 | 8297 | 1.500 |
Why?
|
Drug Eruptions | 2 | 2021 | 335 | 1.170 |
Why?
|
Mentors | 2 | 2024 | 671 | 1.100 |
Why?
|
Kenya | 9 | 2024 | 758 | 1.090 |
Why?
|
Coronavirus Infections | 6 | 2020 | 3100 | 1.050 |
Why?
|
Pneumonia, Viral | 6 | 2020 | 3223 | 1.040 |
Why?
|
Blister | 2 | 2023 | 90 | 0.930 |
Why?
|
Acquired Immunodeficiency Syndrome | 3 | 2023 | 2203 | 0.910 |
Why?
|
International Cooperation | 5 | 2024 | 1432 | 0.870 |
Why?
|
Herpes Genitalis | 4 | 2008 | 148 | 0.840 |
Why?
|
Vaccines | 2 | 2021 | 841 | 0.820 |
Why?
|
Lymphangitis | 1 | 2022 | 15 | 0.790 |
Why?
|
Yaws | 1 | 2020 | 3 | 0.730 |
Why?
|
Surgical Equipment | 1 | 2021 | 58 | 0.720 |
Why?
|
Chickenpox | 1 | 2021 | 95 | 0.720 |
Why?
|
Buruli Ulcer | 1 | 2020 | 11 | 0.720 |
Why?
|
Microscopy, Confocal | 3 | 2024 | 1965 | 0.710 |
Why?
|
Skin | 5 | 2023 | 4489 | 0.710 |
Why?
|
Elephantiasis, Filarial | 1 | 2020 | 31 | 0.710 |
Why?
|
Onchocerciasis | 1 | 2020 | 28 | 0.700 |
Why?
|
Leprosy | 1 | 2020 | 125 | 0.690 |
Why?
|
Exanthema | 2 | 2022 | 502 | 0.680 |
Why?
|
Developing Countries | 4 | 2021 | 2911 | 0.680 |
Why?
|
Health Resources | 3 | 2020 | 949 | 0.660 |
Why?
|
Pemphigoid, Bullous | 1 | 2021 | 109 | 0.660 |
Why?
|
Dermoscopy | 1 | 2020 | 73 | 0.660 |
Why?
|
Herpesvirus 2, Human | 4 | 2008 | 191 | 0.650 |
Why?
|
Dermatologic Agents | 2 | 2024 | 315 | 0.640 |
Why?
|
Herpes Simplex | 2 | 2021 | 472 | 0.640 |
Why?
|
Herpes Zoster | 1 | 2021 | 252 | 0.630 |
Why?
|
Leishmaniasis, Cutaneous | 1 | 2020 | 137 | 0.630 |
Why?
|
Communicable Diseases, Emerging | 1 | 2020 | 150 | 0.600 |
Why?
|
Herpesvirus 8, Human | 1 | 2020 | 254 | 0.590 |
Why?
|
Social Stigma | 1 | 2024 | 788 | 0.570 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2021 | 497 | 0.570 |
Why?
|
Urticaria | 3 | 2022 | 151 | 0.540 |
Why?
|
Policy Making | 1 | 2020 | 546 | 0.540 |
Why?
|
Qualitative Research | 3 | 2024 | 3138 | 0.530 |
Why?
|
Humans | 96 | 2024 | 765956 | 0.520 |
Why?
|
Research Support as Topic | 1 | 2020 | 696 | 0.520 |
Why?
|
Publishing | 1 | 2023 | 835 | 0.500 |
Why?
|
Leadership | 2 | 2024 | 1392 | 0.490 |
Why?
|
Health Services Accessibility | 3 | 2023 | 5506 | 0.490 |
Why?
|
Disease Outbreaks | 7 | 2023 | 1759 | 0.470 |
Why?
|
Community Health Services | 1 | 2020 | 657 | 0.470 |
Why?
|
Pandemics | 10 | 2021 | 8701 | 0.440 |
Why?
|
Bleomycin | 3 | 2022 | 491 | 0.390 |
Why?
|
Skin Neoplasms | 4 | 2021 | 5849 | 0.380 |
Why?
|
Point-of-Care Systems | 1 | 2020 | 1217 | 0.370 |
Why?
|
Vincristine | 3 | 2022 | 1039 | 0.360 |
Why?
|
Immunization, Secondary | 2 | 2024 | 373 | 0.350 |
Why?
|
Keratosis, Actinic | 2 | 2021 | 71 | 0.340 |
Why?
|
Biopsy | 2 | 2021 | 6763 | 0.340 |
Why?
|
Vaccination | 7 | 2024 | 3426 | 0.330 |
Why?
|
Antiretroviral Therapy, Highly Active | 2 | 2014 | 1899 | 0.310 |
Why?
|
Herpes Simplex Virus Vaccines | 1 | 2008 | 17 | 0.310 |
Why?
|
Sexual Behavior | 6 | 2012 | 2193 | 0.290 |
Why?
|
Africa South of the Sahara | 7 | 2020 | 751 | 0.280 |
Why?
|
Etoposide | 2 | 2022 | 636 | 0.280 |
Why?
|
Practice Guidelines as Topic | 3 | 2021 | 7425 | 0.270 |
Why?
|
AIDS-Related Opportunistic Infections | 2 | 2020 | 664 | 0.240 |
Why?
|
Primary Health Care | 3 | 2020 | 4736 | 0.230 |
Why?
|
Disease Susceptibility | 2 | 2021 | 1789 | 0.230 |
Why?
|
Anti-HIV Agents | 2 | 2019 | 4559 | 0.220 |
Why?
|
Benzoyl Peroxide | 1 | 2024 | 22 | 0.220 |
Why?
|
Adult | 28 | 2024 | 223038 | 0.220 |
Why?
|
Salicylic Acid | 1 | 2024 | 60 | 0.220 |
Why?
|
Hypersensitivity | 2 | 2024 | 1168 | 0.220 |
Why?
|
Dicarboxylic Acids | 1 | 2024 | 75 | 0.220 |
Why?
|
Colposcopy | 1 | 2024 | 151 | 0.220 |
Why?
|
Circumcision, Male | 3 | 2011 | 148 | 0.220 |
Why?
|
Severity of Illness Index | 5 | 2022 | 15880 | 0.210 |
Why?
|
Uganda | 3 | 2024 | 1353 | 0.210 |
Why?
|
Administration, Cutaneous | 2 | 2024 | 715 | 0.200 |
Why?
|
Marriage | 1 | 2004 | 351 | 0.200 |
Why?
|
Delivery of Health Care | 2 | 2017 | 5369 | 0.200 |
Why?
|
Isotretinoin | 1 | 2024 | 135 | 0.200 |
Why?
|
Equipment Design | 2 | 2020 | 3481 | 0.200 |
Why?
|
Doxycycline | 1 | 2024 | 349 | 0.190 |
Why?
|
Academies and Institutes | 2 | 2023 | 326 | 0.190 |
Why?
|
Paclitaxel | 2 | 2022 | 1728 | 0.180 |
Why?
|
Angioedema | 1 | 2022 | 184 | 0.180 |
Why?
|
Middle Aged | 18 | 2024 | 223004 | 0.180 |
Why?
|
Herpesvirus 3, Human | 1 | 2021 | 159 | 0.180 |
Why?
|
Immunophilins | 1 | 2000 | 20 | 0.170 |
Why?
|
Transients and Migrants | 1 | 2023 | 170 | 0.170 |
Why?
|
Consumer Advocacy | 1 | 2020 | 83 | 0.170 |
Why?
|
Spironolactone | 1 | 2024 | 415 | 0.170 |
Why?
|
Male | 29 | 2024 | 363691 | 0.170 |
Why?
|
Authorship | 1 | 2023 | 288 | 0.170 |
Why?
|
Microbiological Techniques | 1 | 2020 | 96 | 0.170 |
Why?
|
Incidence | 7 | 2020 | 21480 | 0.160 |
Why?
|
Disease Progression | 3 | 2023 | 13631 | 0.160 |
Why?
|
Female | 27 | 2024 | 396101 | 0.160 |
Why?
|
Societies, Medical | 2 | 2022 | 3956 | 0.160 |
Why?
|
Delayed Diagnosis | 1 | 2022 | 452 | 0.150 |
Why?
|
Acne Vulgaris | 1 | 2024 | 352 | 0.150 |
Why?
|
United States | 8 | 2023 | 72898 | 0.150 |
Why?
|
Biomedical Technology | 1 | 2020 | 210 | 0.150 |
Why?
|
Ventilators, Mechanical | 1 | 2020 | 291 | 0.150 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2020 | 335 | 0.150 |
Why?
|
Photochemotherapy | 2 | 2021 | 826 | 0.150 |
Why?
|
Simplexvirus | 1 | 2021 | 807 | 0.150 |
Why?
|
Community Networks | 1 | 2019 | 203 | 0.140 |
Why?
|
Prevalence | 7 | 2021 | 15839 | 0.140 |
Why?
|
Interferon-alpha | 1 | 2022 | 910 | 0.140 |
Why?
|
Doxorubicin | 2 | 2014 | 2230 | 0.140 |
Why?
|
Drug Therapy, Combination | 3 | 2024 | 6309 | 0.140 |
Why?
|
Sexually Transmitted Diseases | 3 | 2008 | 667 | 0.140 |
Why?
|
Retinal Ganglion Cells | 2 | 2000 | 812 | 0.140 |
Why?
|
Cicatrix | 1 | 2023 | 798 | 0.130 |
Why?
|
Optic Nerve | 1 | 2000 | 567 | 0.130 |
Why?
|
Urban Health | 4 | 2007 | 530 | 0.130 |
Why?
|
Tacrolimus | 1 | 2000 | 753 | 0.130 |
Why?
|
Foot | 1 | 2020 | 573 | 0.130 |
Why?
|
Young Adult | 6 | 2024 | 59886 | 0.130 |
Why?
|
Health Facilities | 1 | 2021 | 577 | 0.130 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2020 | 618 | 0.120 |
Why?
|
Viral Vaccines | 1 | 2021 | 597 | 0.120 |
Why?
|
Standard of Care | 1 | 2020 | 567 | 0.120 |
Why?
|
Selection, Genetic | 1 | 2020 | 878 | 0.120 |
Why?
|
Interdisciplinary Communication | 1 | 2021 | 932 | 0.120 |
Why?
|
Awareness | 1 | 2019 | 653 | 0.120 |
Why?
|
Dermatitis, Atopic | 1 | 2022 | 729 | 0.120 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 747 | 0.120 |
Why?
|
Hand | 1 | 2020 | 909 | 0.120 |
Why?
|
Adolescent | 13 | 2024 | 88832 | 0.120 |
Why?
|
Africa | 3 | 2022 | 725 | 0.120 |
Why?
|
RNA, Messenger | 4 | 2022 | 12769 | 0.120 |
Why?
|
Body Height | 1 | 2020 | 1562 | 0.110 |
Why?
|
Immune Reconstitution Inflammatory Syndrome | 1 | 2014 | 61 | 0.110 |
Why?
|
Time Factors | 4 | 2020 | 40065 | 0.110 |
Why?
|
Psoriasis | 1 | 2020 | 919 | 0.100 |
Why?
|
Feasibility Studies | 2 | 2021 | 5302 | 0.100 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2020 | 953 | 0.100 |
Why?
|
Self Report | 1 | 2024 | 3771 | 0.100 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2024 | 2047 | 0.100 |
Why?
|
Evidence-Based Medicine | 2 | 2024 | 3685 | 0.100 |
Why?
|
Cost-Benefit Analysis | 3 | 2022 | 5526 | 0.100 |
Why?
|
Stochastic Processes | 3 | 2008 | 358 | 0.090 |
Why?
|
Epidemics | 1 | 2017 | 514 | 0.090 |
Why?
|
Antineoplastic Agents | 1 | 2014 | 13648 | 0.090 |
Why?
|
Biomedical Research | 2 | 2020 | 3458 | 0.090 |
Why?
|
Tretinoin | 1 | 2014 | 524 | 0.090 |
Why?
|
Malawi | 1 | 2012 | 315 | 0.090 |
Why?
|
Mutation, Missense | 1 | 2020 | 2589 | 0.090 |
Why?
|
Review Literature as Topic | 1 | 2012 | 297 | 0.090 |
Why?
|
Academic Medical Centers | 1 | 2021 | 2780 | 0.090 |
Why?
|
Disease Management | 1 | 2021 | 2535 | 0.090 |
Why?
|
Liposomes | 1 | 2014 | 788 | 0.090 |
Why?
|
Cross-Sectional Studies | 6 | 2023 | 26313 | 0.090 |
Why?
|
Consensus | 1 | 2020 | 3202 | 0.090 |
Why?
|
Tuberculosis | 1 | 2023 | 2012 | 0.080 |
Why?
|
Early Detection of Cancer | 1 | 2024 | 3236 | 0.080 |
Why?
|
Longitudinal Studies | 2 | 2022 | 14749 | 0.080 |
Why?
|
World Health Organization | 1 | 2014 | 1328 | 0.080 |
Why?
|
Healthcare Disparities | 2 | 2021 | 3412 | 0.070 |
Why?
|
Risk-Taking | 2 | 2011 | 1021 | 0.070 |
Why?
|
Polyethylene Glycols | 1 | 2014 | 1188 | 0.070 |
Why?
|
HIV Seropositivity | 3 | 2004 | 961 | 0.070 |
Why?
|
Meta-Analysis as Topic | 1 | 2012 | 1370 | 0.070 |
Why?
|
Sexual Partners | 1 | 2012 | 804 | 0.070 |
Why?
|
Immunosuppressive Agents | 1 | 2000 | 4209 | 0.070 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2019 | 2159 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2014 | 10383 | 0.070 |
Why?
|
Neoplasm Staging | 1 | 2021 | 11206 | 0.070 |
Why?
|
Risk Factors | 6 | 2021 | 74836 | 0.070 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 11868 | 0.060 |
Why?
|
Fluorouracil | 2 | 2021 | 1648 | 0.060 |
Why?
|
Anti-Bacterial Agents | 1 | 2024 | 7478 | 0.060 |
Why?
|
Quality Improvement | 1 | 2020 | 3853 | 0.060 |
Why?
|
Extramarital Relations | 1 | 2004 | 6 | 0.060 |
Why?
|
Benin | 1 | 2004 | 12 | 0.060 |
Why?
|
Diagnosis, Differential | 2 | 2019 | 12976 | 0.060 |
Why?
|
Cameroon | 1 | 2004 | 79 | 0.060 |
Why?
|
Cortodoxone | 1 | 2024 | 18 | 0.060 |
Why?
|
Adrenal Cortex Hormones | 2 | 2024 | 1880 | 0.060 |
Why?
|
Tetracyclines | 1 | 2024 | 64 | 0.050 |
Why?
|
Zambia | 1 | 2004 | 273 | 0.050 |
Why?
|
Malta | 1 | 2023 | 6 | 0.050 |
Why?
|
Retinoids | 1 | 2024 | 99 | 0.050 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2020 | 8927 | 0.050 |
Why?
|
Propionates | 1 | 2024 | 180 | 0.050 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 8041 | 0.050 |
Why?
|
Contraceptives, Oral, Combined | 1 | 2024 | 116 | 0.050 |
Why?
|
Injections, Intralesional | 1 | 2024 | 281 | 0.050 |
Why?
|
Minocycline | 1 | 2024 | 168 | 0.050 |
Why?
|
Age Factors | 3 | 2020 | 18380 | 0.050 |
Why?
|
Monkeypox virus | 1 | 2022 | 43 | 0.050 |
Why?
|
Health Policy | 1 | 2014 | 2698 | 0.050 |
Why?
|
Skin Pigmentation | 1 | 2024 | 279 | 0.050 |
Why?
|
Rural Population | 1 | 2012 | 2317 | 0.050 |
Why?
|
Family Practice | 1 | 2004 | 508 | 0.050 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 12509 | 0.050 |
Why?
|
Hyperventilation | 1 | 2001 | 78 | 0.050 |
Why?
|
HIV-1 | 2 | 2008 | 6944 | 0.050 |
Why?
|
Diclofenac | 1 | 2021 | 68 | 0.040 |
Why?
|
Chlamydia Infections | 1 | 2004 | 364 | 0.040 |
Why?
|
Nails | 1 | 2022 | 298 | 0.040 |
Why?
|
Hospitalization | 1 | 2020 | 10808 | 0.040 |
Why?
|
Microfibrils | 1 | 2020 | 16 | 0.040 |
Why?
|
Indians, South American | 1 | 2020 | 34 | 0.040 |
Why?
|
Nerve Crush | 1 | 2000 | 79 | 0.040 |
Why?
|
Heredity | 1 | 2020 | 149 | 0.040 |
Why?
|
Sex Factors | 2 | 2020 | 10602 | 0.040 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 2000 | 425 | 0.040 |
Why?
|
Advisory Committees | 1 | 2023 | 796 | 0.040 |
Why?
|
Pilot Projects | 2 | 2024 | 8733 | 0.040 |
Why?
|
Prognosis | 1 | 2020 | 29921 | 0.040 |
Why?
|
Hair | 1 | 2022 | 508 | 0.040 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12057 | 0.040 |
Why?
|
Tacrolimus Binding Proteins | 1 | 2000 | 199 | 0.040 |
Why?
|
Immunity, Humoral | 1 | 2022 | 605 | 0.040 |
Why?
|
Geographic Information Systems | 1 | 2019 | 280 | 0.040 |
Why?
|
Nigeria | 1 | 2020 | 782 | 0.030 |
Why?
|
Sensitivity and Specificity | 3 | 2007 | 14652 | 0.030 |
Why?
|
Botswana | 1 | 2020 | 1057 | 0.030 |
Why?
|
Faculty | 1 | 2020 | 384 | 0.030 |
Why?
|
Peru | 1 | 2020 | 887 | 0.030 |
Why?
|
Lost to Follow-Up | 1 | 2017 | 124 | 0.030 |
Why?
|
Treatment Outcome | 2 | 2022 | 65189 | 0.030 |
Why?
|
Cryosurgery | 1 | 2021 | 479 | 0.030 |
Why?
|
Cell Count | 1 | 2000 | 1823 | 0.030 |
Why?
|
Rats, Wistar | 1 | 2000 | 1884 | 0.030 |
Why?
|
Administration, Oral | 1 | 2024 | 4015 | 0.030 |
Why?
|
Lidocaine | 1 | 1999 | 550 | 0.030 |
Why?
|
Public Opinion | 1 | 2019 | 482 | 0.030 |
Why?
|
DNA Primers | 1 | 2000 | 2825 | 0.030 |
Why?
|
Language | 1 | 2024 | 1550 | 0.030 |
Why?
|
Homosexuality | 2 | 1992 | 267 | 0.030 |
Why?
|
Follow-Up Studies | 1 | 2016 | 39194 | 0.030 |
Why?
|
Gene Frequency | 1 | 2020 | 3624 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2000 | 4562 | 0.030 |
Why?
|
Blotting, Western | 1 | 2000 | 5020 | 0.030 |
Why?
|
Information Dissemination | 1 | 2019 | 1142 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2022 | 4528 | 0.020 |
Why?
|
Bisexuality | 1 | 1992 | 295 | 0.020 |
Why?
|
Age Distribution | 2 | 2008 | 2858 | 0.020 |
Why?
|
Self Care | 2 | 1992 | 800 | 0.020 |
Why?
|
Public Health | 1 | 2022 | 2680 | 0.020 |
Why?
|
Health Promotion | 1 | 2019 | 2208 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2020 | 3615 | 0.020 |
Why?
|
Africa, Eastern | 1 | 2007 | 76 | 0.020 |
Why?
|
Africa, Western | 1 | 2007 | 160 | 0.020 |
Why?
|
Rats | 2 | 2000 | 23707 | 0.020 |
Why?
|
Aged | 4 | 2019 | 171114 | 0.020 |
Why?
|
Research Design | 2 | 2019 | 6208 | 0.020 |
Why?
|
Venereology | 1 | 2004 | 3 | 0.010 |
Why?
|
Chronic Disease | 1 | 2019 | 9347 | 0.010 |
Why?
|
Urban Population | 1 | 2011 | 2040 | 0.010 |
Why?
|
Disease Transmission, Infectious | 1 | 2008 | 560 | 0.010 |
Why?
|
England | 1 | 2004 | 533 | 0.010 |
Why?
|
Rural Health | 1 | 2004 | 301 | 0.010 |
Why?
|
Chlamydia trachomatis | 1 | 2004 | 240 | 0.010 |
Why?
|
Asthma | 1 | 2001 | 6270 | 0.010 |
Why?
|
Patient Education as Topic | 1 | 1992 | 2334 | 0.010 |
Why?
|
Pregnancy | 1 | 2023 | 30258 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2020 | 12807 | 0.010 |
Why?
|
Counseling | 1 | 2008 | 1551 | 0.010 |
Why?
|
Nimodipine | 1 | 1999 | 56 | 0.010 |
Why?
|
Dizocilpine Maleate | 1 | 1999 | 171 | 0.010 |
Why?
|
Rats, Long-Evans | 1 | 1999 | 380 | 0.010 |
Why?
|
Patient Acceptance of Health Care | 1 | 1992 | 3229 | 0.010 |
Why?
|
Computer Simulation | 1 | 2011 | 6255 | 0.010 |
Why?
|
Focus Groups | 1 | 2004 | 1459 | 0.010 |
Why?
|
Models, Statistical | 1 | 2011 | 5089 | 0.010 |
Why?
|
Retrospective Studies | 3 | 2022 | 81515 | 0.010 |
Why?
|
Sex Distribution | 1 | 2001 | 2263 | 0.010 |
Why?
|
Models, Theoretical | 1 | 2008 | 3564 | 0.010 |
Why?
|
Health Care Costs | 1 | 2008 | 3242 | 0.010 |
Why?
|
Syndrome | 1 | 2001 | 3271 | 0.010 |
Why?
|
Child | 1 | 2023 | 80563 | 0.010 |
Why?
|
Neuroprotective Agents | 1 | 1999 | 959 | 0.010 |
Why?
|
San Francisco | 1 | 1992 | 166 | 0.010 |
Why?
|
Clinical Nursing Research | 1 | 1991 | 13 | 0.010 |
Why?
|
Animals | 2 | 2000 | 168759 | 0.010 |
Why?
|
Internal-External Control | 1 | 1991 | 347 | 0.010 |
Why?
|
Cell Survival | 1 | 1999 | 5746 | 0.000 |
Why?
|
Algorithms | 1 | 2008 | 14071 | 0.000 |
Why?
|
Affect | 1 | 1991 | 1498 | 0.000 |
Why?
|
Health Behavior | 1 | 1992 | 2650 | 0.000 |
Why?
|
Quality of Life | 1 | 1991 | 13461 | 0.000 |
Why?
|